Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 The Conference Forum ... Innovations to Advance Clinical Trials conference taking place on ... Boston, MA. , Disruptive thinkers from Novartis, Pfizer, ... share bold approaches to reduce expensive infrastructure, engage patients ... needs to be big, or novel, or it must ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that ... Marcum LLP Microcap Conference, May 30, in New ... Lyons , CPA, Chief Financial Officer of Cleveland BioLabs, ... 30 at 1:30 p.m. Eastern Time.  A live and archived ... Investors page of the Cleveland BioLabs website at www.cbiolabs.com ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2
... Medical Education Agency Expanding Industry Connections, MOUNTAINSIDE, ... independent, full-service medical education company,today announced the hiring ... Weinstein will leverage his experience in medical education ... to joining L&M, he,served as Manager of Publication ...
... The increased emphasis on,safety by regulatory agencies worldwide ... and requires rapid, cost-effective and,resource intensive actions by ... can be found in consulting organizations. GZP,has already ... errors,that can lead to adverse regulatory action by ...
... Oct. 14 Based on its recent,analysis of ... ISTO,Technologies, Inc. with the 2008 North American Frost ... InQu(R) Bone Graft Extender and Substitute,scaffold. InQu represents ... its proprietary biomaterial-based platform technology., Although spinal ...
Cached Biology Technology:L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 2Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 4
(Date:5/22/2013)... Harvard physicists have developed a novel technique that can ... a process that is one of the most important, ... described in a paper in Nature , post-doctoral ... Dr. Melanie Schnell of the Center for Free-Electron Laser ... relies on finely-tuned microwave fields to identify molecular variants ...
(Date:5/22/2013)... new, streamlined approach to genetic engineering drastically reduces ... genes into bacteria, the workhorses of biotechnology, scientists ... Synthetic Biology , the method paves the way ... drug development, environmental cleanup and other activities. , ... integrating, a piece of the genetic material DNA ...
(Date:5/22/2013)... The feared Legionella pneumophila bacteria is responsible ... pneumonia. In order to infect us, this pathogen has ... and go unnoticed in our cells, thus avoiding these ... the Basque biosciences research centre, CIC bioGUNE, in which ... the USA and the National Supercomputation Centre in Barcelona ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... ... 8, 2009 National Instruments (Nasdaq: NATI ), a ... leader and pioneer in manufacturing automation using robotics technology, today ... with DENSO robotic arms. The collaboration increases productivity and performance ...
... , , , , , LONDON, ... Security Product Innovation Award is presented to Sagem Securite (Safran ... recognises the company,s expertise in advanced biometric technology and its ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , "Sagem Securite ...
... WI, December 15, 2009 Economics, environmental impacts, social ... influence the overall success of an agroecosystem. Positive or ... individuals and social groups to continuously adapt farming and ... learning theory suggests that knowledge is gained as a ...
Cached Biology News:National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Experiential learning teaches change and adaptation 2
... unique quantitative and qualitative capabilities of the ... LC/MS/MS Systems with the new Tempo nano ... a rapid solution for high sensitivity validation ... extensive sample preparation with high instrument selectivity ...
... reliable and compact GC-8A is Shimadzu's basic ... and simple to use, the GC-8A supports ... control, on column injection port(s), and analog ... models are available. The GC-8A is only ...
... Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) Competitor ... and efficient method for studying ... using fluorescence polarization (FP). The ... domain (PPARGamma-LBD) with an N-terminal ...
... call for critical, but time-consuming optimization ... siRNA transfection protocols resulting in less ... be used to efficiently transfect adherent ... without increased cytotoxicity. From start to ...
Biology Products: